Ownership history in X-Square Capital, LLC · 10 quarters on record
This page tracks every 13F SEC filing in which X-Square Capital, LLC reported a position in Adaptimmune Therapeutics Plc (ADAP). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | UNCHANGED | 10,673 | — | 0% | 0.00% | $1K | — |
| 2025 Q2 | UNCHANGED | 10,673 | — | 0% | 0.00% | $3K | — |
| 2025 Q1 | UNCHANGED | 10,673 | — | 0% | 0.00% | $2K | — |
| 2024 Q4 | REDUCED | 10,673 | -7 | -0.1% | 0.00% | $6K | — |
| 2024 Q3 | REDUCED | 10,680 | -12 | -0.1% | 0.00% | $10K | — |
| 2024 Q2 | REDUCED | 10,692 | -500 | -4.5% | 0.00% | $10K | — |
| 2024 Q1 | REDUCED | 11,192 | -16,233 | -59.2% | 0.01% | $14K | — |
| 2023 Q4 | ADDED | 27,425 | +654 | +2.4% | 0.01% | $22K | — |
| 2023 Q3 | UNCHANGED | 26,771 | — | 0% | 0.02% | $25K | — |
| 2023 Q2 | INITIATED | 26,771 | — | — | 0.02% | $25K | — |
As of 2025 Q4 — sorted by position size